维拉帕米与三磷酸腺苷终止室上性心动过速临床电生理对照观察  

CLINICAL ELECTROPHYSIOLOGY OF THE TERMINATION OF SUPRAVENTRICULAR TACHYCARDIA (SVT) BY VERAPAMIL AND ADENOSINE TRIPHOSPHATE(ATP)

作　　者：邹路云[1] 刘爱纯[1] 冯国珍[1] 刘仁光[1] 李莉[1] 刘俐纯[1] 

机构地区：[1]辽宁省锦州医学院附属医院循环科,辽宁省锦州医学院附属医院心功能科,辽宁省锦州市药品检验所

出　　处：《中国循环杂志》1994年第7期395-397,共3页Chinese Circulation Journal

摘　　要：对经食管心房调搏诱发的４２例室上性心动过速（ＳＶＴ）患者进行维拉帕米和三磷酸腺苷（ＡＴＰ）终止ＳＶＴ的临床电生理自身对照观察。结果表明：维拉帕米和ＡＴＰ终止ＳＶＴ有效率分别为９７．８％和８８．１％（Ｐ＞０．０５），均具有作用快、疗效高的优点。但ＡＴＰ有引起明显的一过性胸闷、呼吸困难和对窦房结、房室结抑制的副作用，临床用药应引起注意；维拉帕米对血压有轻度影响，但作用相对平稳，在无禁忌证的情况下可列为首选。The clinical electrophysiology of the termination of esophageal atrial pacing induced SVT by verapamil 10 mg in 20 ml 10% glucose iv. or ATP 20 mg in 2 ml 10% glucose iv. was studied. Esophageal atrial pacing induced SVT in 42 cases. The results showed that the effective rates of termination of SVT by verapamil and ATP were 97. 85% and 88. 09% (p>0. 05) , respectively , both of them were highly effective with fast action. But ATP might cause marked transient chest discomfort,dyspnea and symptoms due to depressed sinoatrial and atrio-ventricular node function. The hypotensive effect of verapamil was milder than that of ATP. So verapamil is of first choice in cases with no contraindications.

关 键 词：三磷酸腺苷 维拉帕米 心动过速 

分 类 号：R972.2[医药卫生—药品]